Melphalan Therapy in Myelomatosis

Melphalan therapy of polycythemia vera.

Twenty-seven patients with p. vera and adverse hematologic effects were whose proliferative disease required the infrequent. To date one patient has desuppression of bone marrow function veloped refractory anemia and evidence were treated with melphalan for periods of myelofibrosis. Four patients have deof 20 to 72 months. The response was veloped acute leukemia but none of these rated as good ...

Protein analyses in myelomatosis.

The criteria for the admission of patients to the Medical Research Council's (MRC) myeloma trials are the finding of abnormal plasma cells in bone marrow films or sections and in addition either of characteristic skeletal lesions demonstrated radiologically or of characteristic protein changes in the serum or urine. Ninety per cent of the patients in the first myeloma trial satisfied all three ...

Thromboembolic complications in myelomatosis.

claims for sick benefit reached a weekly figure of approximately 450% above the seasonal average. Strains of the Hong Kong variant of influenza virus A2 were isolated in the area. Returns from councils of absence owing to illness, believed to be influenza, during December and January were as follows. Unvaccinated 164 Off sick 41 Vaccinated once only 27 Off sick 7 Vaccinated twice 85 Off sick ni...

Intrathecal Melphalan Therapy of Human Neoplastic Meningitis

We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x IO5 or 5 x IO6 TE-67I human rhabdomyosarcoma cells or 5 x 10'' D-54 MG human glioma cells and were treated with melphalan on days 8. 5, or 5, respectively. M...

Antibody formation in myelomatosis.